jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Feb. 09, 2023

Oct. 28, 2024

jRCT2031220627

A Single Dose Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-2214 in Healthy Japanese Participants

Single Dose Study of MK-2214 in Healthy Japanese Participants

Tanaka Yoshiyuki

MSD K.K.

KITANOMARU SQUARE,1-13-12,Kudan-kita,Chiyoda-ku,Tokyo 102-8667,Japan

+81-3-6272-1957

msdjrct@msd.com

MSDJRCT inquiry mailbox

MSD K.K.

KITANOMARU SQUARE,1-13-12,Kudan-kita,Chiyoda-ku,Tokyo 102-8667,Japan

+81-3-6272-1957

msdjrct@msd.com

Complete

Mar. 17, 2023

Mar. 17, 2023
48

Interventional

randomized controlled trial

double blind

placebo control

parallel assignment

other

Healthy male or female aged 18 to 75 years old with BMI 18 to 30 kg/m2

Has a history of clinically significant abnormalities or diseases

18age old over
75age old under

Both

Alzheimer's Disease

Single i.v. dosing
Panel A: MK-2214 700mg or Placebo
Panel B: MK-2214 2100mg or Placebo
Panel C and D: MK-2214 4200mg or Placebo

Adverse event

AUC0-inf, AUC0-last, AUC0-140d, AUC0-28d, Cmax, Tmax, t1/2, CL and Vz

MSD K.K.
P-One Clinic, Keikokai Medical Corp. Institutional Review Board
View Tower Hachioji 4F, 8-1, Yokamachi, Hachioji-shi, Tokyo

+81-42-625-5216

irbjimukyoku@keikokai-gr.or.jp
Approval

Feb. 27, 2023

Yes

http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

なし

none

History of Changes

No Publication date
4 Oct. 28, 2024 (this page) Changes
3 July. 22, 2024 Detail Changes
2 Mar. 26, 2023 Detail Changes
1 Feb. 09, 2023 Detail